This study will evaluate efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) as measured by the proportion of participants achieving hepatitis C virus (HCV) RNA below the lower limit of quantification (LLOQ) 12 weeks after the last dose of LDV/SOF (sustained virologic response (SVR) 12).